This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Yeh, H. S. Articles by Berenson, J. R. Search for Related Content PubMed PubMed Citation Articles by Yeh, H. S. Articles by Berenson, J. R.

Treatment for Myeloma Bone Disease

Authors' Affiliation: Institute for Myeloma and Bone Cancer Research, West Hollywood, California

Requests for reprints: James R. Berenson, Institute for Myeloma and Bone Cancer Research, 9201 West Sunset Boulevard, Suite 300, West Hollywood, CA 90069. Phone: 310-623-1214; Fax: 310-623-1120; E-mail: jberenson{at}imbcr.org.

Multiple myeloma (MM) is a B cell malignancy characterized by enhanced bone loss commonly associated with diffuse osteopenia, focal lytic lesions, pathologic fractures, hypercalcemia, and bony pain. Bone destruction in MM results from asynchronous bone turnover wherein increased osteoclastic bone resorption is not accompanied by a comparable increase in bone formation. Consequently, patients with MM frequently require radiation therapy, surgery, and analgesic medications. The recent development of minimally invasive surgical procedures such as kyphoplasty allows patients with myeloma with vertebral compression fractures to have immediate improvement in their quality of life with shorter hospital stays. Bisphosphonates are specific inhibitors of osteoclastic activity, and these agents have been evaluated in patients with MM with bone disease during the past 15 years. Monthly i.v. infusions of either pamidronate or zoledronic acid have reduced the skeletal complications among patients with MM and are now a mainstay of myeloma therapy. Orally administered bisphosphonates, in contrast, have shown little ability to slow the development of skeletal complications in these patients. Although preclinical studies suggest that nitrogen-containing bisphosphonates have potent antitumor effects, clinical trials will be necessary, probably at higher doses given more slowly, to establish their possible antitumor effects clinically. Moreover, recent advances in the use of bone-seeking radiopharmaceuticals make these attractive therapeutic candidates to combine with bisphosphonates or radiosensitizing drugs (e.g., bortezomib) to achieve a synergistic effect. As our understanding of the pathophysiology of myeloma bone disease continues to grow, new target therapies will continue to emerge, offering new and more advanced options for the management of myeloma bone disease.

This article has been cited by other articles:

				A. U. Ural and F. Avcu Therapeutic Role of Bisphosphonate and Radiation Combination in the Management of Myeloma Bone Disease Clin. Cancer Res., June 1, 2007; 13(11): 3432 - 3432. [Full Text] [PDF]